Navigation Links
Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
Date:12/4/2007

Results of SHEPHERD Phase III Open Label Trial Published in Online Edition

of the Journal Blood

CHESHIRE, Conn., Dec. 4 /PRNewswire-FirstCall/ -- Soliris(R) (eculizumab) therapy reduced hemolysis and improved fatigue, overall quality of life and anemia in a diverse population of patients with a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH), according to an analysis of the Phase III SHEPHERD study published online in Blood, the journal of the American Society of Hematology. The article is currently available at http://bloodjournal.hematologylibrary.org/cgi/content/abstract/blood-2007-0 6- 094136v1 and will be published in a future print edition of Blood.

Soliris, Hemolysis and PNH

Soliris, developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), is the first therapy approved for the treatment of patients with PNH, a rare, debilitating and life-threatening blood disorder defined by the destruction of red blood cells, or hemolysis. Soliris is indicated for the treatment of patients with PNH to reduce hemolysis. In patients with PNH, hemolysis can cause thromboses, kidney disease, liver dysfunction, disabling fatigue, impaired quality of life, recurrent pain, shortness of breath, pulmonary hypertension, intermittent episodes of dark colored urine (hemoglobinuria), and anemia.(1-3)

Efficacy in a Broader Population

"The data from the SHEPHERD study confirm the earlier findings from the placebo-controlled TRIUMPH study," said Robert A. Brodsky, M.D., lead author of the SHEPHERD publication and Director, Division of Hematology and Associa
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
10. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
11. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Iliad Neurosciences, Inc., a ... diagnosing and treating Autism Spectrum Disorders (ASD) announced today ... with The Research Foundation for The State University of ... provide a new biomarker to identify an abnormality in ... ASD. This biomarker is expected to be available for ...
(Date:9/18/2014)... , Sept. 18, 2014  ePharmaSolutions, ... was recognized as the Disruptive Innovator of ... ePharmaONE cloud-based eClinical platform. This solution includes ... trial master file (eTMF), a remote monitoring ... ePharmaSolutions, ReferralPlus+ patient screening and matching technology. ...
(Date:9/18/2014)... PLAINSBORO, N.J. , Sept. 18, ... of the National Hemophilia Foundation,s (NHF) new three-year ... support to people with hemophilia and their families/caregivers ... that can impede disease management. The curriculum for ... With Your Provider About Pain , focuses on ...
Breaking Medicine Technology:Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3
... 1 RX-3341 Results -, NEW HAVEN, Conn., ... "Company"), a development-stage company focused on the,discovery and ... infections, today announced the initiation of a Phase,2 ... compound RX-3341 in,the treatment of complicated skin and ...
... Will Remain as the Clinical Gold Standard ... New Report from Decision Resources, WALTHAM, Mass., ... leading research and advisory firms focusing on pharmaceutical ... in preventing,recurrence of depressive mood episodes in patients ...
Cached Medicine Technology:Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections 2Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections 3Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder 2
(Date:9/19/2014)... 19, 2014 VogueQueen.com has ... that will make ladies more beautiful at their weddings. ... everyone can afford. The company’s new products are made ... offering great savings for all the global clients. ... extremely beautiful. I have ordered several items on its ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Defendants ... http://www.xareltolawsuitcenter.com ) currently pending in Pennsylvania’s Philadelphia Court ... claims filed on behalf of out-of-state plaintiffs dismissed, ... on September 11th, the defendants maintain that circumstances ... in the lawsuits have no connection to Pennsylvania. ...
(Date:9/18/2014)... 2014 Dr. David A. F. Ellis ... American Academy of Facial Plastic and Reconstructive Surgery and ... Division of Facial Plastic Surgery. He is recognized ... surgery. , Dr. Ellis will be presenting on ... presenting on injection techniques and various treatments for complications ...
(Date:9/18/2014)... to diverse communities may boost infants, social learning, according ... in the park or supermarket could help children be ... different from them, researchers found. "Research has ... interacting with and learning from people who are different ... psychology professor, said in a university news release. ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 "Medical staff ... care while also maintaining the patient's privacy," said one ... with this idea in order to supply caregivers with ... , They created a prototype for The Helper to ... enables staff to turn patient onto his or her ...
Breaking Medicine News(10 mins):Health News:VogueQueen.com’s New Line Of Cheap Wedding Dresses Aims To Attract Chic Ladies 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 3Health News:Dr. David A. F. Ellis Has Been Invited to Speak at a Conference of the American Academy of Facial Plastic and Reconstructive Surgery in Orlando, Florida 2Health News:Study: Exposure to Diversity Might Boost Baby's Social Skills 2
... , RE: American Psychological Association 116th Annual Convention in ... 162A, Meeting Level 1, Boston Convention and Exhibition Center. ... tops and two high-speed printers. We will also provide ... transmission and APA staff resources. This room will also ...
... Joel Ario today announced that the Insurance Department ... the state to,hear from consumers and other affected ... and Independence Blue Cross, plus related,changes, will impact ... held July 8 in Pittsburgh, July 10 in ...
... Officials Not to Privatize,Veterans, Health Care, WASHINGTON, ... today launched a nationwide radio ad campaign,urging Congress ... of,Veterans, Affairs. In the ad, AFGE urges presidential ... for the VA., "As the nation,s highest ...
... release is available in French . , Montreal, ... traumatic experience and, in some cases, emotional and physical pain ... phantom limb syndrome, Universit de Montral graduate student Emma Duerden ... for a major study. , Our main goal is to ...
... of cancers that affect tissues such as muscle, fat, ... Italy on 13-14 May to discuss the latest information ... for therapy. , The 2nd Symposium on Sarcoma and ... for Medical Oncology (ESMO), will include sessions on the ...
... International Inc., found to have committed patent and ... ... Mannatech,Incorporated (Nasdaq: MTEX ) a leading developer and provider ... federal court,jury in the Northern District of Texas found that ...
Cached Medicine News:Health News:Highlights for APA's 116th Annual Convention in Boston, Aug. 14-17 2Health News:Highlights for APA's 116th Annual Convention in Boston, Aug. 14-17 3Health News:Highlights for APA's 116th Annual Convention in Boston, Aug. 14-17 4Health News:Insurance Department to Hold Statewide Meetings on Proposed Consolidation of Independence Blue Cross, Highmark 2Health News:AFGE Launches Nationwide Ad Campaign Aimed at Funding the VA 2Health News:2nd ESMO symposium on soft tissue carcinomas and GIST 2Health News:2nd ESMO symposium on soft tissue carcinomas and GIST 3Health News:Jury Validates Key Mannatech Technology Patents Involving Its Ambrotose(R) Glyconutrient Products 2Health News:Jury Validates Key Mannatech Technology Patents Involving Its Ambrotose(R) Glyconutrient Products 3
... This functional brace is designed for the ... and fibula. The preformed design provides post ... removal of internal or external fixation. The ... and below the fracture site, increasing vascularity ...
... Brace features a multi-axial hinge that duplicates ... altering kinematics. The infinite degree of adjustment ... and extension control of the knee. , ... tibia in correct anatomical alignment. The precision ...
... is a revolutionary cast replacement system for ... leg and foot. , ,A self-adjusting ... and in conjunction with a rigid lattice ... time of fracture or rupture healing can ...
... the constant demands of mobilizing patients quickly. ... necessary to fit bilateral KAFO's.,The complete kit ... knee joints , 4 Copolymer thigh support ... bands , Ortho-wick™ Padding for thigh , ...
Medicine Products: